Controlled ovarian hyperstimulation leads to high progesterone and estradiol levels during early pregnancy. 2014

Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
Department of Obstetrics and Gynaecology, Oulu University Hospital, PO Box 5000, 90014 Oulu, Finland ilkka.jarvela@oulu.fi.

OBJECTIVE Are there differences in estrogen and progesterone secretion in singleton pregnancies, up to Week 11, between spontaneous pregnancies, after controlled ovarian hyperstimulation and fresh embryo transfer (COH + ET) and after frozen embryo transfer in a spontaneous cycle (FET)? CONCLUSIONS Serum progesterone and estradiol (E2) concentrations after COH + ET were higher in early pregnancy, lasting up to Week 7-8, than FET and spontaneous pregnancies, while hormone levels after FET did not differ from spontaneous pregnancies. BACKGROUND The risk of adverse perinatal outcomes after COH + ET seems to be increased when compared with spontaneous pregnancies. One of the reasons suggested for this is related to ovarian hyperstimulation. METHODS This was a prospective cohort study consisting of three different groups of pregnant women which were followed-up weekly until Week 11 of their pregnancies. The spontaneous pregnancy group consisted of 41 women, the COH + ET group consisted of 39 and the FET group consisted of 30 women. METHODS Women in the control group with spontaneous conception were recruited from local prenatal clinics. Women in the COH + ET and FET groups were recruited from the Reproductive Unit of Oulu University Hospital. At each visit, a three-dimensional ultrasonography was performed to examine the ovarian volumes and vascularization. A blood sample was drawn to analyse progesterone and E2 levels. The pregnancy outcome was included in the analysis. RESULTS At pregnancy Week 5, the serum progesterone levels were higher after the COH + ET (median 312, inter-quartile range 183-480 nmol/l), when compared with the spontaneous (63, 52-80 nmol/l; P < 0.001) and FET (74, 48-96 nmol/l; P < 0.001) pregnancies. At Week 11, the P (189, 124-260 nmol/l) was still higher in the COH + ET group (FET 101, 78-120 nmol/l, P < 0.001; spontaneous 115, 80-139 nmol/l, P < 0.01) than the other two groups. The E2 levels at Week 5 were also significantly higher after COH + ET (4.1, 2.2-6.6 nmol/l) than in the spontaneous pregnancies (1.1, 0.7-1.6 nmol/l, P < 0.001) or after FET (0.7, 0.6-0.9 nmol/l, P < 0.001). The volume of the ovaries and the intraovarian vasculature in the COH + ET group were significantly higher when compared with the other two groups (P < 0.001). The birthweight was negatively correlated with the serum P (R -0.340, P < 0.01) and E2 (R= -0.275, P < 0.05) in pregnancy Weeks 5-8. In the multivariate analysis evaluating the factors affecting birthweight of the newborn, the significant factors were the length of gestation, maternal height and progesterone or E2 secretion during Weeks 5-8. CONCLUSIONS Because of the low number of patients in this study, larger cohort studies are required to confirm the findings. CONCLUSIONS The findings here indicate that COH-induced increased luteal activity should be evaluated by measuring steroid levels or the ovarian size or vascularity, rather than number of oocytes retrieved. If unphysiologically high steroid activity during pregnancy after COH contributes to the risk of adverse perinatal outcomes after fresh embryo transfer, milder stimulation protocols or even freezing of all of the embryos should be considered. BACKGROUND This study was supported by a research grant from the Academy of Finland. The authors declare no conflicts of interest.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D010062 Ovulation Induction Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum. Ovarian Stimulation,Ovarian Stimulations,Stimulation, Ovarian,Stimulations, Ovarian
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011256 Pregnancy Outcome Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO. Outcome, Pregnancy,Outcomes, Pregnancy,Pregnancy Outcomes
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001724 Birth Weight The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms. Birthweight,Birth Weights,Birthweights,Weight, Birth,Weights, Birth
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot

Related Publications

Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
June 1996, Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy,
Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
June 1998, Fertility and sterility,
Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
November 2018, Hypertension in pregnancy,
Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
February 2001, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
February 2010, Fertility and sterility,
Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
November 2022, JBRA assisted reproduction,
Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
August 2001, Fertility and sterility,
Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
January 2013, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
November 1994, Fertility and sterility,
Ilkka Y Järvelä, and Sari Pelkonen, and Outi Uimari, and Kaarin Mäkikallio, and Katri Puukka, and Aimo Ruokonen, and Aydin Tekay, and Hannu Martikainen
November 2015, Fertility and sterility,
Copied contents to your clipboard!